{"id":"W4210665852","doi":"10.1016/j.lungcan.2022.01.023","title":"Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Afatinib; Medicine; Pembrolizumab; Internal medicine; Lung cancer; Clinical endpoint; Oncology; Adverse effect; Population; Carcinoma; Epidermal growth factor receptor; Surgery; Gastroenterology; Cancer; Gefitinib; Immunotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006732862,0.0002180311,0.0004142404,0.0001221024,0.0002525032,0.000006445708,0.0001389779,0.00003704992,0.0003898269],"category_scores_gemma":[0.000008041724,0.00013269,0.0001045304,0.0004947203,0.00003152777,0.00007916911,0.0001265342,0.0001980812,1.021967e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009205391,"about_ca_system_score_gemma":0.0003818111,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00067005,"about_ca_topic_score_gemma":0.000497368,"domain_scores_codex":[0.9983096,0.00005982674,0.0004064205,0.0003377555,0.0006159849,0.0002703764],"domain_scores_gemma":[0.9991418,0.00002853233,0.0002681806,0.000413405,0.00008488631,0.00006320477],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0113383,0.007052623,0.9597656,0.0004925965,0.0001978111,0.00005664922,0.01892778,0.001280631,0.0001078617,4.440606e-7,0.0001311289,0.0006485636],"study_design_scores_gemma":[0.1284958,0.007587841,0.857193,0.0004402,0.001111594,0.000003066068,0.001306523,0.001541687,0.001994572,7.425653e-7,0.00009263441,0.0002323637],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994601,0.001527938,0.000003280376,0.000139156,0.0002648206,0.003226876,0.00008124062,0.00001898661,0.0001367494],"genre_scores_gemma":[0.9974406,0.000006796009,0.00003707888,0.00007228192,0.00004800766,0.001438611,0.00002404923,0.00005335897,0.0008791524],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1171575,"threshold_uncertainty_score":0.5410941,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007170244930122876,"score_gpt":0.3156310337756659,"score_spread":0.3084607888455431,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}